



Protected when completed

This is a draft version only. Do not submit to any funding organization. Only the final version from the History page can be submitted.

Dr. Don Thiwanka Dilshan Wijeratne

Correspondence language: English

Date of Birth: 1/23

Canadian Residency Status: Canadian Citizen

Country of Citizenship: Canada

Contact Information

The primary information is denoted by (*)

Address

Primary Affiliation (*)

Queens University
76 Stuart Street
Kingston Ontario K7L 3N6
Canada

Telephone

Work (*) 011-613-549 6666

Email

Work (*) dtdw@queensu.ca



Protected when completed

This is a draft version only. Do not submit to any funding organization. Only the final version from the History page can be submitted.

Dr. Don Wijeratne

Degrees

2008/9 - 2010/6	Master's Thesis, Clinical Epidemiology, University of Toronto Degree Status: Completed
1999/11 - 2007/3	Doctorate, M.D, University of Colombo Degree Status: Completed

Credentials

2015/10	Sub-specialist in General Internal Medicine, Royal College of Physicians and Surgeons of Canada
2014/6	FRCPC, Royal College of Physicians and Surgeons of Canada
2007/11	Accreditation as a certified Lecturer in University Education SEDA (Staff and Education Development Association- United Kingdom) - (2008), SEDA (Staff and Education Development Association)
2013/7 - 2015/6	Fellow-General Internal Medicine Training Program, Queen's University at Kingston
2010/7 - 2013/6	Resident-Core Internal Medicine Training Program, Queen's University at Kingston

Recognitions

2024/5	Witness for the Standing Senate Committee on Official Languages Senate of Canada
2024/3	Optimizing Clinical Competencies by Building Epidemiology Capacity in Sri Lanka Royal College Canada
2016/3	Excellence in Clinical Teaching award PARO Queen's University at Kingston
2015/3 - 2017/3	Canadian Patient safety Institute studentship award 2014/2015 Canadian Patient Safety Institute
2009/3	Featured as a "New Researcher" in the Ontario Institute of Cancer Research, Annual report 2009. Ontario Institute for Cancer Research

Employment

2022/6	Adjunct Scientist. Institute of Clinical Evaluative Sciences. (ICES) Epidemiology, Health Sciences, Queen's University at Kingston
2022/3	Adjunct Scientist, Queen's Cancer Research Institute Oncology, Health Sciences, Queen's University at Kingston
2021/7	Cross appointed to Department of Public Health Sciences Public Health Sciences, Queen's University, Queen's University at Kingston
2015/8	Associate Professor, Division of General Internal Medicine Medicine, Faculty of Health Sciences, Queen's University at Kingston
2015/7	Research lead to the residency training committee, General Internal Medicine fellowship program. Queen's University Medicine, Medicine, Queen's University at Kingston
2014/7 - 2015/6	Locum Internist Sault Ste. Marie Area district Hospital and Timmins District Hospital
2009/6 - 2010/6	Post Doctoral Fellowship in Management of Chronic Disease in Older Adults Medicine, Medicine, Women's College Research Institute
2008/6 - 2010/6	Post doctoral researcher Li Ka Shing Knowledge Institute, Medicine, St. Michael's Hospital
2008/6 - 2010/6	Graduate Student Health Policy Management and Evaluation, Medicine, University of Toronto

Affiliations

The primary affiliation is denoted by (*)

(*) 2010/7 Post Graduate trainee (Resident/Fellow) (2010-2015) Faculty -2015 to date, Queen's University at Kingston

Research Funding History

Awarded [n=8]

2024/6 - 2025/6 Co-applicant	Translational Institute of Medicine, Queen's, Optimizing clinical competencies of Internal Medicine residents by structured epidemiology training Funding Sources: Queen's University Translational Institute of Medicine Total Funding - 20,000 Funding Competitive?: Yes
2024/3 - 2025/3 Co-applicant	Principal Applicant, Operating grant, Royal College Canada. Optimizing Clinical Competencies by Building Epidemiology Capacity in Sri Lanka Funding Sources: Principal Operating Grant Optimizing Clinical Competencies by Building Epidemiology Capacity in Sri Lanka Total Funding - 90,000 Funding Competitive?: Yes
2024/1 - 2025/3 Principal Applicant	Understanding Disparities in Receipt of Guideline Concordant Care Among Immigrants with Colorectal Cancer in Ontario

Funding Sources:

Institute of Clinical Evaluation Sciences
ICES
Total Funding - 25,000
Funding Competitive?: Yes

2021/7 - 2024/7

Principal Applicant

Department of Medicine Research Award- CIHR Pillars category. Remote Outreach
Secure Text Messaging on Discharge to Prevent Readmissions of patients with Chronic
Obstructive Pulmonary Disease, A M-COPD pilot study (\$20000)

Funding Sources:

Canadian Institutes of Health Research (CIHR)
2021 Department of Medicine Research Award- CIHR Pillars category. Remote Outreach
Secure Text Mess
Total Funding - 20,000
Funding Competitive?: Yes

2022/6 - 2024/6

Co-applicant

Southeastern Ontario Academic Medical Organization, Global Health grant for optimizing
antibiotic stewardship in Sri Lanka- Co-PI

Funding Sources:

Southeastern Ontario Academic Medical Organization
Global Health grant
Total Funding - 50,000
Funding Competitive?: Yes

2019/5 - 2022/12

Principal Applicant

Southeastern Ontario Academic Medical Organization- Innovation Grant. Muti-modal
approach to reducing COPD readmission . Wijeratne DTD (PI), Srivastava S (\$200000)
(Extended to Dec 2022 due to Covid)

Funding Sources:

Southeastern Ontario Academic Medical Organization
Innovation grant
Total Funding - 200,000
Funding Competitive?: Yes

2017/10 - 2022/10

Principal Applicant

Department of Medicine Queen's - Innovation fund recipient (\$25,000)

Funding Sources:

Queen's University
Innovation Fund
Total Funding - 25,000
Funding Competitive?: Yes

2016/8 - 2020/10

Principal Applicant

Queen's University research initiation grant (\$30,000) 2017/21

Funding Sources:

Queen's University
Medicine- Research initiation grant
Total Funding - 30,000
Funding Competitive?: Yes

Publications

Journal Articles

1. Dhruv Vinay, Iresh Jayaweera, Meghan Bowman, Don Thiwanka D Wijeratne. (2025). Patient-reported outcomes in clinical trials assessing the effectiveness of cabotegravir + rilpivirine long-acting injections as antiretroviral therapy: A systematic review. *HIV Medicine*. 26(9): 1343-1355.
Accepted
2. U Jayarajah, H Wijayalathge, K Peiris, T Wijeratne, S Gunasekera, S Seneviratne. (2024). Quality of life following completion of treatment among Sri Lankan women with breast cancer. *European Journal of Cancer*. 200(supple 1): 113664.
Published
3. Wijeratne DT. (2024). A commentary on: A Practical Guide to Using Oral JAK Inhibitors for Atopic Dermatitis from the International Eczema Council. *Practice Update*. 4(1): 170400.
4. U Jayarajah, J Mithushan, WPH Priyan, K Peiris, H Wijayalathge, T Wijeratne, S Gunasekera, S Seneviratne. (2024). Prevalence of depression, anxiety and stress and its associated factors among women with breast cancer in Sri Lanka. *European Journal of Cancer*. 200(suppl 1): 113663.
5. M Bowman, M Jalink, I Sharpe, S Srivastava, DT Wijeratne. (2023). Videoconferencing interventions and COPD patient outcomes: A systematic review. *Journal of Telemedicine and Telecare*. .(.): ..
Published
6. Thanabalasingam SJ, Ranawaka SS, Gunarathna SSC, Yathev B, Booth CM, Seneviratne S, Gunasekera S, Wijeratne DTD. (2023). Patient Satisfaction With Breast Cancer Care Delivery at the National Cancer Institute of Sri Lanka: Does Language Play a Role?. *JCO Glob Oncol*.9: :e2200366.
7. Gyawali, Bishal, Meghan Bowman, Isobel Sharpe, Matthew Jalink, Siddhartha Srivastava, and Don Thiwanka Wijeratne. (2023). A systematic review of eHealth technologies for breast cancer supportive care. *Cancer Treatment Reviews*. 114: 102519.
8. Sarith Ranawaka, Sathika Gunarathna, Sanjeeva Gunasekera, Christopher M Booth, Matthew Jalink, Laura M Carson, Scott Berry, Bishal Gyawali, Sanjeewa Seneviratne, Don Thiwanka Wijeratne. (2023). Breast Cancer-Related Financial Toxicity in Sri Lanka: Insights From a Lower Middle-Income Country With Free Universal Public Healthcare. *The Oncologist*. 29(2): e259-e265.
Published
9. L Scott, LL Truong, RL Houlden, DT Wijeratne. (2023). Screening and Management Recommendations for Type 2 Diabetes in Women with Breast Cancer. *Canadian Journal of Diabetes*. :. :.
10. R Peters, N Wijeratne, M Bowman, DT Wijeratne. (2023). Five practical strategies to get a grip on large group cooperative virtual learning in medical education. *Canadian Medical Education Journal*. :. :.
11. K Wright, GC Digby, B Gyawali, R Jad, A Menard, FY Moraes,. (2023). Malignant Superior Vena Cava Syndrome: A Scoping Review. *Journal of Thoracic Oncology*. :. :.
12. Samantha Sarabia, Brandan Ranjith, Sahil Koppikar, Don Thiwanka Wijeratne. (2022). Efficacy of JAK Inhibitors in the Treatment of Psoriasis and Psoriatic Arthritis A Systematic Review and Meta-Analysis. *Seminars in Arthritis and Rheumatism*. -(-): -.
In Press
13. Wijeratne DTD, Gunasekera S, Booth CM, Berry S, Jalink M, Carson LM, Gyawali B, Promod H, Jayarajah U, Seneviratne S. (2022). Colorectal Cancer Treatment Characteristics and Concordance With Guidelines in Sri Lanka: Results From a Hospital-Based Cancer Registry. *JCO Glob Oncol*.8(e2200004): online.
14. S. Seneviratne H. Wijayalathge K. Peiris S. Gunasekera T. Wijeratne. (2022). Post-treatment quality of life among Sri Lankan women with breast cancer. *REHABILITATION/SURVIVORSHIP*. 175(1): S55.

- [15.](#) Seneviratne, S., Wijayalathge, H., Peiris, K., Gunasekara, S. and Wijeratne, DTD. (2022). Depression, anxiety and stress among women with breast cancer in Sri Lanka. *European Journal of Cancer*. *European Journal of Cancer*. 175: S55.
- [16.](#) Truong, Lan-Linh, Laura Scott, Raveen S. Pal, Mathew Jalink, Sanjeeva Gunasekara, and Don Thiwanka Wijeratne. (2022). Cancer and cardiovascular disease: can understanding the mechanisms of cardiovascular injury guide us to optimise care in cancer survivors?. *ecancer*. 16: online.
- [17.](#) Wijeratne DTD, Housin A, Lajkosh K, Loughheed MD, Yu Xiong P, Barber D, Doliszny KM, Archer SL. (2022). Using Health Administrative data to Identify Patients with Pulmonary Hypertension: A single center, proof of concept validation study in Ontario, Canada. *Pulmonary Circulation*. 12(1): e12040. Published
18. Sarabia, S., Ranjith, B., Koppikar, S., & Wijeratne,. (2022). Efficacy and safety of JAK inhibitors in the treatment of psoriasis and psoriatic arthritis: a systematic review and meta-analysis. *BMC rheumatology*. 6(1): 1-16.
19. Sanjeeva Gunasekera, Sanjeeva Seneviratne, Hasitha Pramod, Laura M Carson, Scott Berry, Christopher M Booth, Thiwanka Wijeratne. (2022). Addressing unmet needs of cancer care in a lower middle income country by establishing an electronic hospital based cancer registry. *Journal of Clinical Oncology*. 40(16 suppl): e13621-e13621.
- [20.](#) Wijeratne DT, Bowman M, Sharpe I, Srivastava S, Jalink M, Gyawali B. (2021). Text Messaging in Cancer-Supportive Care: A Systematic Review. *cancers*. 13(14): -. Published
- [21.](#) Susan J. Thanabalasingam , Brandon Ranjith, Robyn Jackson Don Thiwanka Wijeratne. (2021). Cannabis and its derivatives for the use of motor symptoms in Parkinson's Disease: A Systematic Review and Meta-Analysis. *Advances in Neurological Disorders*. -(-): -. Published
Refereed?: Yes
- [22.](#) Gunasekera S, Seneviratne S, Jalink M, Joseph N, Ariyaratna Y, Booth CM, Wijeratne DTD. (2021). Clinical Oncology Workload in Sri Lanka: Infrastructure, Supports, and Delivery of Clinical Care. *JCO Glob Oncology*. -(-): -. Published
- [23.](#) Don Thiwanka Wijeratne, Sanjeeva Gunasekera, Christopher M. Booth, Hasitha Pramod, Matthew Jalink, Umesh Jayarajah & Sanjeeva Seneviratne. (2021). Demographic, tumour, and treatment characteristics of female patients with breast cancer in Sri Lanka; results from a hospital-based cancer registry. *BMC Cancer*. -(-): -. Published
- [24.](#) Don Thiwanka Wijeratne MD, Kristin Wright MD , Bishal Gyawali MD. (2021). Do we need prediction tools to risk-stratify treatment strategies for chemotherapy induced Febrile Neutropenia?. *Journal of Clinical Oncology*. -(-): -. Published
- [25.](#) Mehras Motamed, Jaff, Zardasht, Meredith Poole, Wijeratne, Don. (2021). Dysphagia Megalatriensis in an 87-Year-Old Woman. *CJGIM*. -(-): -. Published
- [26.](#) Isobel Sharpe, Meghan Bowman, Andrew Kim, Siddhartha Srivastava, Don Thiwanka Wijeratne. (2021). Strategies to prevent readmissions to hospital for COPD: A Scoping Review. *Chronic Obstructive Pulmonary Disease*. -(-): -. Published

27. [Wijeratne Don Thiwanka, Booth Christopher M, Seneviratne Sanjeewa, Gyawali Bishal, Jalink Matt, Soysa Malinithi, Abhayaratna Sachith, Promod Hasitha, Wijesinghe Punika, Gunasekera Sanjeeva. \(2021\). Healthcare delivery for non-communicable diseases among breast cancer survivors in Sri Lanka: Is there a missed opportunity?. *ecancer*. -\(-\): -. Published](#)
28. [Wijeratne, Don Thiwanka, Kristin Wright, and Bishal Gyawali. \(2021\). Risk-Stratifying Treatment Strategies for Febrile Neutropenia—Tools, Tools Everywhere, and Not a Single One That Works?. *JCO Oncology Practice*. 17\(11\): 651-654. Published](#)
29. [Wijeratne, Don Thiwanka, Karen Okrainec, Tara Gomes, Diana Martins, Muhammad M. Mamdani, Paula A. Rochon, Gerald A. Evans, and Sudeep S. Gill. \(2021\). Language proficiency and warfarin-related adverse events in older immigrants and Canadian residents: a population-based cohort study. *Drugs & Therapy Perspectives*. -\(-\): -. Published](#)
30. [S Wong, G Zhang, H Welihinda, DTD Wijeratne. \(2020\). Polysulfonate Resins in hyperkalemia – A systematic review. *Canadian Journal of Kidney Health and Disease*. 7\(-\): -. Published
Refereed?: Yes](#)
31. [Don Thiwanka Wijeratne, Sanjeeva Gunasekara, Christopher M Booth, Hasitha Promod, Sanjeewa Seneviratne. \(2020\). Patterns of Cancer Care at the National Cancer Institute Sri Lanka Assessing Care Provision and Unmet Needs through an Electronic Database. *Journal of Cancer Policy*. 25\(-\): -. Published
Refereed?: Yes, Open Access?: Yes](#)
32. [Don Thiwanka Wijeratne, Nazik Hammad, Bishal Gyawali. \(2020\). Gender differences in outcomes of cancer patients with COVID: Signal or noise? Commentary. *EClinical Medicine by Lancet*. -\(-\): -. Published
Refereed?: Yes, Open Access?: Yes](#)
33. [Ibrahim S., Shuster S., Aina D., Wijeratne D. \(2020\). Seven ways to get a grip on facilitating bedside team rounding. *Canadian Medical Education Journal*. 26;12\(1\): e85-e88. Published
Refereed?: Yes](#)
34. [Amir Nazarian, Andrea Grin, Don Thiwanka Wijeratne. \(2019\). Ixekizumab Associated New-Onset Inflammatory Bowel Disease. *American College of Gastroenterology - Case reports*. 7\(2\): e00316. Published](#)
35. [Ping Yu Xiong, Zardasht Jaff, Christine L. D'Arsigny, Stephen L. Archer, Don Thiwanka Wijeratne. \(2019\). Evaluation of the Impact of an Echocardiographic Diagnosis of Pulmonary Hypertension on Patient Outcomes. *Canadian Journal of Cardiology- Open*. 2\(5\): 328-336. Published
Refereed?: Yes, Open Access?: Yes](#)
36. [Lip Alyssa, Warias Ashley, Shamseddin M Khaled, Thomson Benjamin, Wijeratne D Thiwanka. \(2019\). Effect of Bisphosphonates on Bone Health in Adult Renal Transplant Patients: Beyond the First Year Posttransplant-A Systematic Review and Meta-Analysis. *Canadian journal of kidney health and disease*. 6: 2054358119858014. Published
Refereed?: Yes](#)
37. [Panamsky, L., Ford, A., Srivastava, S., & Wijeratne, D. T. \(2019\). Deprescribing Potentially Inappropriate Medications in a Tertiary Care Centre in Ontario. *Canadian Journal of General Internal Medicine*. 14: 30-35. Published
Refereed?: Yes](#)

38. Wijeratne D Thiwanka, Lajkosz Katherine, Brogly Susan B, Loughheed M Diane, Jiang Li, Housin Ahmad, Barber David, Johnson Ana, Doliszny Katharine M, Archer Stephen L. (2018). Increasing Incidence and Prevalence of World Health Organization Groups 1 to 4 Pulmonary Hypertension: A Population-Based Cohort Study in Ontario, Canada. *Circulation. Cardiovascular quality and outcomes*. 11(2): e003973.
Published
Refereed?: Yes
39. Gunasekera, Sanjeeva, Seneviratne, Sanjeewa, Wijeratne, Thiwanka, Booth, Christopher M. (2018). Delivery of Cancer Care in Sri Lanka. *Journal of Cancer Policy*. 18: 20-24.
Published
Refereed?: Yes
- [40.](#) Audrey Tran, Andrey Vishnyakov, Wijeratne DTD. (2018). Risk of Heart Failure with DPP-4 Inhibitors: A Meta-Analysis. *Canadian Journal of Diabetes* 42 (5), S6. 42(5): S6.
Published
41. Wijeratne, Don Thiwanka, Srivastava, Siddhartha, Chan, Barry, Hopman, Wilma, Thomson, Benjamin. (2018). Sustainability of physical exam skills in a resident-led curriculum in a large internal medicine program with competency based medical education. *Canadian Medical Education Journal*. 9(4): 78-92.
Published
Refereed?: Yes

Conference Publications

1. Don Thiwanka Wijeratne, Sanjeewa Senaratne, Matthew Jalink, Christopher M Booth, Hasitha Promod, Sanjeeva Gunasekera. Improving cancer care in Sri Lanka through an Electronic database. An International collaboration. Canadian Conference on Global Health, Canada
Conference Date: 2021/11
Paper
Refereed?: Yes, Invited?: Yes
2. H Pramod, S Seneviratne, S Gunasekera, C Booth, D T Wijeratne. Developing Breast and Colorectal cancer database using DHIS platform. Global Digital, health Forum, Washington, DC, United States of America
Conference Date: 2019/12
Abstract
3. Ping Yu Xiong, Zardasht Jaff, Christine L. D'Arsigny, Stephen L. Archer, Don Thiwanka Wijeratne. Evaluation of the Impact of an Echocardiographic Diagnosis of Pulmonary Hypertension on Patient Outcomes. American heart Association conference 2019, Philadelphia, Pennsylvania, United States of America
Conference Date: 2019/11
Poster
4. Lip A, Varis A, Shamsudeen K, Wijeratne DTD. Safety of Bisphosphonates in renal transplant patients. Systematic review. Canadian Society of Internal Medicine 2018, Banff, AB, Canada
Conference Date: 2018/10
Poster

Presentations

1. (2024). Critical appraisal for clinicians. Seminar series, Sri Lanka
Main Audience: General Public
Invited?: Yes, Keynote?: No

2. (2023). Learning the ropes in Global Health. Guest Lecture. MSc public health. Queen's University., Canada
Main Audience: Knowledge User
Invited?: Yes, Keynote?: No
3. (2022). Lessons learnt in Global Oncology in an LMIC. Seminar in public health – Queen's University, Department of Public Health, Canada
Main Audience: Knowledge User
Invited?: Yes, Keynote?: No
4. (2022). Addressing the low hanging fruit in cancer care, LMICs using Sri Lanka as an example, July 2022. Medical grand rounds – Queen's University, Department of Medicine., Canada
Main Audience: Knowledge User
Invited?: Yes, Keynote?: No
5. Don Thiwanka Wijeratne, Sanjeewa Senaratne, Matthew Jalink, Christopher M Booth, Hasitha Promod, Sanjeeva Gunasekera. (2022). Improving cancer care in Sri Lanka through an Electronic database. An International collaboration. Canadian Conference on Global Health, Canada
Main Audience: Researcher
Invited?: Yes, Keynote?: No

Student/Postdoctoral Supervision

Master's Thesis [n=2]

2020/3 - 2022/6	Isobel Sharpe, Queen's University
Co-Supervisor	Thesis/Project Title: Efficacy of remote monitoring of patients with cancer Present Position: Research Associate
2019/3 - 2022/5	Meghan Bowmen, Queen's University
Co-Supervisor	Thesis/Project Title: Assessing equitable access to care among hospitalized patients with COPD Present Position: Research associate/Program manager

Doctorate [n=1]

2015/1	Research Supervisor for Resident led research projects (population based, systematic reviews), Queens University
Principal Supervisor	Thesis/Project Title: Array of research topics on chronic disease during residency training Present Position: -

Date Submitted: 2024-02-27 12:32:38

Confirmation Number: 1750184

Template: CIHR Biosketch

Dr. Bishal Gyawali

Correspondence language: English

Sex: Male

Date of Birth: 8/21

Canadian Residency Status: Permanent Resident

Country of Citizenship: Nepal

Contact Information

The primary information is denoted by (*)

Address

Primary Affiliation (*)

Cancer Care and Epidemiology
Queen's University
Queen's Cancer Research Institute
10 Stuart Street, Kingston K7L3N6
Kingston Ontario K7L3N6
Canada

Telephone

Work (*) 613-5336000 extension: 78509

Email

Work (*) gyawali.bishal@queensu.ca

Website

Corporate <https://oicr.on.ca/researchers/dr-bishal-gyawali/>



Protected when completed

Dr. Bishal Gyawali

Degrees

2013/10 - 2017/9	Doctorate, PhD in Medical Sciences (Medical Oncology), Nagoya University Degree Status: Completed
2005/9 - 2013/1	Bachelor's, Bachelor in Medicine & Bachelor in Surgery, Tribhuvan University, Institute of Medicine Degree Status: Completed

Credentials

2021/6	Academic Oncologist, College of Physicians and Surgeons of Ontario
2019/3 - 2021/5	Clinical Fellow, College of Physicians and Surgeons of Ontario

Recognitions

2023/6	ASCO-Leadership Development Program American Society of Clinical Oncology
2023/4	2023 Azbee Award of Excellence- Gold (Regional and National, 2 separate categories) American Society of Business Publication Editors
2022/12	Current Oncology Young Investigator Award Current Oncology
2022/1	Outstanding Young Researcher from Asia Japanese Society of Medical Oncology
2022/1	Chair for the Global Oncology session at ASCO 2022 Annual Meeting ASCO

Employment

2021/6	Associate Professor Department of Oncology, Health Sciences, Queen's University at Kingston
2021/6	Associate Professor Department of Public Health Sciences, Health Sciences, Queen's University at Kingston
2021/6	Attending Physician Kingston General Hospital
2019/3	Scientist/ Principal Investigator Cancer Care and Epidemiology, Faculty of Health Sciences, Queen's University at Kingston

2019/3	Member Health Policy Council, School of Policy Studies, Queen's University at Kingston
2019/3	Affiliated Faculty Cancer Policy and Biomarkers, Harvard Medical School Boston, Brigham and Women's Hospital
2019/3 - 2021/5	Assistant Professor Public Health Sciences, Health Sciences, Queen's University at Kingston
2019/3 - 2021/5	Clinical Fellow Department of Oncology, Health Sciences, Queen's University at Kingston
2018/2 - 2019/2	Research Fellow Division of Pharmacoepidemiology and Pharmacoeconomics, Harvard Medical School, Brigham and Women's Hospital
2017/5 - 2018/12	Medical Consultant Anticancer Fund, Belgium
2017/10 - 2018/2	Registrar, Staff Physician Civil Service Hospital, Nepal
2017/4 - 2018/2	Visiting faculty Oncology, Cancer Policy, Institute of Cancer Policy, King's College, London, UK
2013/10 - 2017/9	PhD candidate, Medical Oncology Clinical Oncology and Chemotherapy, Graduate School of Medicine, Nagoya University
2012/10 - 2017/9	Postgraduate trainee in Medical Oncology Clinical Oncology and Chemotherapy, Graduate School of Medicine, Nagoya University

Affiliations

The primary affiliation is denoted by (*)

(*) 2021/6 Associate Professor of Oncology, Queen's University at Kingston

Research Funding History

Awarded [n=6]

2021/6 - 2027/5 Principal Investigator	Ontario Institute for Cancer Research (OICR) Clinical Investigator Award Funding Sources: Ontario Institute for Cancer Research (OICR) Clinical Investigator Award Total Funding - 1,200,000 Funding Competitive?: Yes
2023/9 - 2025/8 Principal Investigator	Differences in prices of cancer drugs within and between hospitals to treat gastrointestinal cancers in Nepal Funding Sources: Clinical Teachers' Association of Queen's CTAQ CTAQ Research Endowment Fund Total Funding - 25,000 Funding Competitive?: Yes
2023/7 - 2024/6 Principal Investigator	Financial Toxicity of Cancer Treatment in Canada Funding Sources: Clare Nelson Fund

	Clare-Nelson Bequeth Fund for Cancer Research Total Funding - 20,000 Funding Competitive?: Yes
2022/5 - 2023/4 Principal Investigator	Gairdner Krembil Science Program Grant Funding Sources: Gairdner Krembil Foundation Gairdner Krembil Science Program Grant Total Funding - 12,000 Funding Competitive?: Yes
2020/1 - 2021/7 Principal Applicant	Precision Groundshot: Developing a context-specific and needs-based curriculum to train Primary Care Physicians in Low-and-Middle Income Countries (LMICs) Funding Sources: American Society of Clinical Oncology (ASCO) 2020 Conquer-Cancer BMS Global Oncology Young Investigator Award Total Funding - 50,000 Funding Competitive?: Yes
2019/3 - 2021/4 Principal Investigator	Cancer outcome disparities between First Nation population and other Canadian populations in Ontario Funding Sources: Southeastern Ontario Academic Medical Organization (SEAMO) Clinical Research Fellowship Award Total Funding - 100,000 Funding Competitive?: Yes

Publications

Journal Articles

1. Jenei K, Raymakers AJN, Bayle A, Berger-Thürmel K, Cherla A, Honda K, Jackson CCGA, Karikios D, Trapani D, Berry S, Gyawali B. (2023). Health technology assessment for cancer medicines across the G7 countries and Oceania: an international, cross-sectional study. *Lancet Oncol*.6: 624-635.
2. Madeline Pe, PhD Ahu Alanya, PhD Ragnhild Sorum Falk, PhD Cecilie Delphin Amdal, MD PhD Prof Kristin Bjordal, MD PhD Jane Chang, MPH Paul Cislo, PhD Corneel Coens, MSc Linda Dirven, PhD Rebecca M Speck, PhD Kristina Fitzgerald, MPH Jayne Galinsky, PhD Johannes M Giesinger, PhD Prof Bernhard Holzner, PhD Prof Saskia Le Cessie, PhD Daniel O'Connor, MBChB PhD Kathy Oliver, BA Vivek Pawar, PhD Chantal Quinten, PhD Michael Schlichting, MSc Jinma Ren, MD PhD Satrajit Roychoudhury, PhD Prof Martin J B Taphoorn, MD PhD Prof Galina Velikova, PhD Lisa M Wintner, PhD Ingolf Griebisch, PhD Andrew Bottomley, PhD on behalf of theSISAQOL-IMI Consortium. (2023). Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints in Cancer Clinical Trials-Innovative Medicines Initiative (SISAQOL-IMI): stakeholder views, objectives, and procedures. *Lancet Oncol*. 24.6: e270-e283.
3. Gyawali B, Bowman M, Sharpe I, Jalink M, Srivastava S, Wijeratne DT. (2023). Asystematic review of eHealth technologies for breast cancer supportive care.*Cancer Treat Rev*.114: 102519.
4. Jenei K#, Meyers D, Gyawali B. (2023). Assessmentof Price and Clinical Benefit of Cancer Drugs in Canada, 2011-2020.*JAMA Netw Open*.6: 1-4.
5. Bishal Gyawali, M.D., Ph.D., Aaron S. Kesselheim, M.D., J.D., M.P.H., and Joseph S. Ross, M.D., M.H.S. (2023). The Accelerated Approval Program for Cancer Drugs Finding the Right Balance. *N Engl J Med*. 389(11): 968-971.

6. Jenei K#, Gyawali B*. (2023). Expensive Drug Prices for Rare Cancers: Are Patients Truly Benefitting?. *Healthc Pap.*21(1): 44-51.
7. Sengar M, Fundytus A, Hopman W, Pramesh CS, Radhakrishnan V, Ganesan P, Mathew A, Lombe D, Jalink M, Gyawali B, Trapani D, Roitberg F, De Vries EGE, Moja L, Ilbawi A, Sullivan R, Booth CM. (2022). Cancer Medicines: What Is Essential and Affordable in India?. *JCO Glob Oncol.* 10(12): -. Published
8. Oosting SF, Barriuso J, Bottomley A, Galotti M, Gyawali B,...Piccart M, Cherny NI. (2022). Methodological and reporting standards for quality of life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) credit. *Annals of Oncology.* xxx: 1-9.
9. Gyawali B, Griffiths R, Robinson AG, McInnes MDF, Bedard PL, Booth CM. (2022). Utilization of imaging for active surveillance in testicular cancer: Is real-world practice concordant with guidelines?. *Can Urol Assoc J.* epub: -. Published
10. Kartolo A# and Gyawali B. (2022). Should the control arms of randomized trials have an expiry date?. *Nat Rev Clin Oncol.* epub: -. Published
11. Denburg AE, Fundytus A, Khan MS, Howard SC, Antillon-Klussmann F, Sengar M, Lombe D, Hopman W, Jalink M, Gyawali B, Trapani D, Roitberg F, De Vries EGE, Moja L, Ilbawi A, Sullivan R, Booth CM. (2022). Defining Essential Childhood Cancer Medicines to Inform Prioritization and Access: Results From an International, Cross-Sectional Survey. *JCO Glob Oncol.* epub: -. Published
12. Wells JC, Fundytus A, Sharma S, Hopman WM, Del Paggio JC, Gyawali B, Mukherji D, Hammad N, Pramesh CS, Aggarwal A, Sullivan R, Booth CM. (2022). Randomized Controlled Trials in Lung, Gastrointestinal, and Breast Cancers: An Overview of Global Research Activity. *Curr Oncol.* 29(4): 2530-2538. Published
13. Gyawali B. (2022). Lessons learned from the accelerated approval of cancer drugs. *Clin Adv Hematol Oncol.* Clin Adv Hematol Oncol.20(7): 441-443. Published
Refereed?: Yes
14. Gyawali B, Eisenhauer E, Tregear M, Booth CM. (2022). Progression-free survival: it is time for a new name. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045\(22\)00015-8/fulltext](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(22)00015-8/fulltext). 23: 238-230. Published
15. Gyawali B*, Thapa N, Savage C, Carson LM, Jalink M, Rawal M, Berry S, Sharma Poudyal B. (2022). Training General Practitioners in Oncology: A Needs Assessment Survey From Nepal. *JCO Glob Oncol.* epub: -. Published
16. Wright K, Meyers DE, Chisamore TM, McInnes MDF, Sismondo S, Gyawali B, Prasad V, Booth CM. (2022). Industry Relationships With Medical Oncologists: Who Are the High-Payment Physicians?. *JCO Oncol Pract.* epub: -. Published
17. Sachdev A#, Sharpe I, Bowman M, Booth CM, Gyawali B. (2022). Objective response rate of placebo in randomized controlled trials of anticancer medicines. *EClinical Medicine.*55: 101753. Published

- [18.](#) Wesson W, Galate VL, Sborov DW, McClune B, Goodman AM, Gyawali B, Prasad V, Abbasi S, Mohyuddin GR. (2022). Characteristics of clinical trials for haematological malignancies from 2015 to 2020: A systematic review. *Eur J Cancer*. 167: 152-160.
Published
- [19.](#) Gyawali B*, Booth CM. (2022). Defining clinically important overall survival thresholds: lessons from quality of life. *Nat Rev Clin Oncol*. epub: -.
Published
- [20.](#) Cherny NI, Dafni U, Pentheroudakis G, Piccart M, Zygoura P, Gyawali B, de Vries EGE. (2022). The first ones now, will later be last": understanding the importance of historical context when reading ESMO-MCBS scores. *ESMO Open*. 7(2): 100413.
Published
- [21.](#) Gyawali B, Carson L, Berry S and Moraes F. (2022). Challenges of globalization of cancer drug trials- recruitment in LMICs, approval in HIC. *The Lancet Regional Health – Americas*. epub: -.
Published
- [22.](#) Wijeratne DT, Gunasekara S, Booth CM, Berry S, Jalink M, Carson LM, Gyawali B, Promod H, Jayarajah U, Seneviratne S. (2022). Colorectal Cancer Treatment Characteristics and Concordance With Guidelines in Sri Lanka: Results From a Hospital-Based Cancer Registry. *JCO Glob Oncol*. epub: -.
Published
- [23.](#) Strzebonska K, Blukacz M, Wasylewski MT, Polak M, Gyawali B, Waligora M. (2022). Risk and benefit for umbrella trials in oncology: a systematic review and meta-analysis. *BMC Med*. 20(1): 219.
Published
- [24.](#) Dodkins J, Hopman WM, Wells JC, Lievens Y, Malik RA, Pramesh CS, Gyawali B, Hammad N, Mukherji D, Sullivan PR, Parkes J, Booth CM, Aggarwal A. (2022). Is Clinical Research Serving the Needs of the Global Cancer Burden? An analysis of contemporary global radiotherapy randomised controlled trials. *Int J Radiat Oncol Biol Phys*. 113(3): P500-508.
Published
- [25.](#) Khan SZ, Arecco L, Villarreal-Garza C, Sirohi B, Ponde NF, Habeeb B, Brandão M, Azim HA Jr, Chowdhury AR, Bozovic-Spasojevic I, Kovalenko I, Odhiambo A, Seid FU, Mutombo AB, Petracci F, Vidra R, Altuna SC, Petrova M, Kourie HR, Ozturk MA, Razeti MG, Lengyel CG, Talibova N, Mariamidze E, Sacardo KP, Duma N, Gyawali B, Trapani D, Tagliamento M, Lambertini M. (2022). Knowledge, Practice, and Attitudes of Physicians in Low- and Middle-Income Countries on Fertility and Pregnancy-Related Issues in Young Women With Breast Cancer. *JCO Glob Oncol*. 8: e2100153.
Published
- [26.](#) Van Wambeke S, Vera-Badillo FE, Gyawali B. (2022). Controlling the Control Arm in Metastatic Castration-Resistant Prostate Cancer Trials: Best Standard of Care or the Minimum Standard of Care?. *J Clin Oncol*. 40(14): 1518-1521.
Published
- [27.](#) Gyawali B* and Booth CM. (2022). Cancer treatments should benefit patients: a common-sense revolution in oncology. *Nat Med*. 28(4): 617-620.
Published
28. Lythgoe MP, Desai A, Gyawali B, Savage P, Krell J, Warner JL, Khaki AR. (2022). Cancer Therapy Approval Timings, Review Speed, and Publication of Pivotal Registration Trials in the US and Europe, 2010-2019. *JAMA Netw Open*. epub: -.
Published
- [29.](#) Akhade A, Sirohi B and Gyawali B*. (2022). Global consequences of the US FDA's accelerated approval of cancer drugs. *The Lancet Oncology*. epub: -.
Published

- [30.](#) Li X, Beeghly-Fadiel A, Bhavnani SK, Tavana H, Rubinstein SM, Gyawali B, Riaz IB, Fernandes HD, Warner JL. (2022). Evaluation of Information Theoretic Network Meta-analysis to Rank First-Line Anticancer Regimens for Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer. JAMA Network Open. 5(4): e224361.
Published
- [31.](#) Aggarwal C and Gyawali B. (2022). Aumolertinib in EGFR-Mutant Lung Cancer: Will the Promise of Cost Disruption Ease Access?. J Clin Oncol. epub: -.
Published
Refereed?: Yes
- [32.](#) Samuel JN#, Booth CM, Eisenhauer E, Brundage M, Berry SR, Gyawali B*. (2022). Association of Quality-of-Life Outcomes in Cancer Drug Trials With Survival Outcomes and Drug Class. JAMA Oncol. epub: -.
Published
- [33.](#) Fundytus A, Sengar M, Lombe D, Hopman W, Jalink M, Gyawali B, Trapani D, Roitberg F, De Vries EGE, Moja L, Ilbawi A, Sullivan R, Booth CM. (2021). Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey. Lancet Oncol. epub: -.
Published
- [34.](#) West HJ and Gyawali B. (2021). What Is the Least We Should Expect From New Drugs? The Relative Harm of 'Me-Too' Drug Approvals. ASCO Daily News. -: -.
Published
- [35.](#) Cherla A, Naci H, Kesselheim AS, Gyawali B, Mossialos E. (2021). Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval. JAMA Internal Medicine. epub: -.
Published
- [36.](#) Strzebonska K, Wasylewski MT, Zaborowska L, Polak M, Slugocka E, Stras J, Blukacz M, Gyawali B, Waligora M. (2021). Risk and Benefit for Targeted Therapy Agents in Pediatric Phase II Trials in Oncology: A Systematic Review with a Meta-Analysis. Target Oncol. epub: -.
Published
- [37.](#) Fu M, Naci H, Booth CM, Gyawali B, et al. (2021). Real-world Use of and Spending on New Oral Targeted Cancer Drugs in the US, 2011-2018. JAMA Intern Med. epub: -.
Published
- [38.](#) Thomson S, Witzke N, Gyawali B, Delos Santos S, Udayakumar S, Cardone C, Cheung MC, Chan KKW. (2021). Assessing the benefit of cancer drugs approved by the European Medicines Agency using the European Society for Medical Oncology Magnitude of Clinical Benefit Scale over time. Eur J Cancer. 150: 203-210.
Published
- [39.](#) Luo Z, Gyawali B*, Han S, Shi L, Guan X and Wagner AK. (2021). Can locally developed me-too drugs aid price negotiation? An example of cancer therapies from China. Seminars in Oncology. epub: -.
Published
- [40.](#) Van Wambeke S and Gyawali B. (2021). Atezolizumab in Metastatic Triple-Negative Breast Cancer-No Contradiction in the Eyes of a Dispassionate Observer. JAMA Oncol. epub: -.
Published
- [41.](#) Meyers DE, Chisamore TM, McInnes MDF, Gyawali B, Prasad V and Booth CM. (2021). Industry payments to US physicians for cancer therapeutics: An analysis of the 2016–2018 open payments datasets. Journal of Cancer Policy. epub: -.
Published

42. Wijeratne DT, Booth CM, Seneviratne S, Gyawali B, Jalink M, Soysa M, Abhayaratna S, Promod H, Wijesinghe P, Gunasekera S. (2021). Healthcare delivery for non-communicable diseases among breast cancer survivors in Sri Lanka: Is there a missed opportunity?. *Ecancermedicalscience*. epub: -. Published
43. Meyers DE, Meyers BS, Chisamore TM, Wright K, Gyawali B, Prasad V, Sullivan R, Booth CM. (2021). Trends in drug revenue among major pharmaceutical companies: A 2010-2019 cohort study. *Cancer*. epub: -. Published
44. Sharma S#, Booth C. M., Eisenhauer E. A., and Gyawali B*. (2021). Do Editorialists With Industry-Related Conflicts of Interest Write Unduly Favorable Editorials for Cancer Drugs in Top Journals?. *Journal of the NCCN*. 19(11): -. Published
45. Gyawali B* and Kesselheim A.S. (2021). FDA approval standards for anticancer agents — lessons from two recent approvals in breast cancer. *Nat Rev Clin Oncol*. epub: -. Published
46. Bhanvadia SK, Psutka SP, Burg ML, de Witte R, Dhillon HM, Gyawali B, Morgans AK, Goldstein DA, Smith AB, Sun M, Penson DF. (2021). Financial Toxicity Among Patients with Prostate, Bladder, and Kidney Cancer: A Systematic Review and Call to Action. *Eur Urol Oncol*. epub: -. Published
47. Gyawali B* and Booth CM. (2021). Disease-Free Survival As a Clinical Trial Endpoint: Does It Matter, and to Whom?. *ASCO Daily News*. -: -. Published
48. Gyawali B*, Ross JS, Kesselheim AS. (2021). Fulfilling the Mandate of the US Food and Drug Administration's Accelerated Approval Pathway: The Need for Reforms. *JAMA Intern Med*. epub: -. Published
49. Gyawali B*, D'Andrea E, Franklin JM and Kesselheim AS. (2021). A correlation analysis to assess event-free survival as a trial-level surrogate for overall survival in early breast cancer. *EClinicalMedicine*. epub: -. Published
50. Wijeratne DT, Bowman M, Sharpe I, Srivastava S, Jalink M, Gyawali B. (2021). Text Messaging in Cancer-Supportive Care: A Systematic Review. *Cancers (Basel)*. 13(14): 3542. Published
51. Rubinstein SM, Sethi T, Venepalli NK, Gyawali B, Schwartz C, Rivera DR, Yang PC, Warner JL. (2021). Chemotherapy Knowledge Base Management in the Era of Precision Oncology. *JCO Clin Cancer Inform*. 5: 30-35. Published
52. Subedi R, Dhimal M, Budukh A, Chapagain S, Gyawali P, Gyawali B, Dahal U, Dikshit R, Jha AK. (2021). Epidemiologic Pattern of Cancer in Kathmandu Valley, Nepal: Findings of Population-Based Cancer Registry. *JCO Glob Oncol*. 7: 443-452. Published
53. Sharma S#, Wells JC, Hopman WM, Del Paggio JC, Gyawali B, Hammad N, Hay AE, Booth CM. (2021). Cancer, Clinical Trials, and Canada: Our Contribution to Worldwide Randomized Controlled Trials. *Current Oncology*. 28(2): 1518-1527. Published
54. Basnet BK, Gautam B, Ranabhat K, Paudel BD, Chapagain Acharya S, Bastola SR, Gyawali B. (2021). KRAS Oncogene Mutations in Colorectal Cancer Patients in a Nepalese Tertiary Care Hospital. *J Nepal Health Res Council*. 19(3): 504-507. Published

55. Meyers DE, Jenei K, Chisamore TM, Gyawali B*. (2021). Evaluation of the Clinical Benefit of Cancer Drugs Submitted for Reimbursement Recommendation Decisions in Canada. *JAMA Internal Medicine*. 181(4): 499-508.
Published
56. Gyawali B*, Rome BN, Kesselheim AS. (2021). Regulatory and clinical consequences of negative confirmatory trials of accelerated approval cancer drugs: retrospective observational study. *The BMJ*. epub: -.
Published
57. Fundytus A, Wells JC, Sharma S, Hopman WM, Del Paggio JC, Gyawali B, Mukherji D, Hammad N, Pramesh CS, Aggarwal A, Sullivan R, Booth CM. (2021). Industry Funding of Oncology Randomised Controlled Trials: Implications for Design, Results and Interpretation. *Clin Oncol*. epub: -.
Published
58. Wells JC, Sharma S, Del Paggio JC, Hopman W, Gyawali B, Mukherji D, Hammad N, Pramesh CS, Aggarwal A, Sullivan R and Booth C. (2021). An Analysis of Contemporary Oncology Randomized Clinical Trials From Low/Middle-Income vs High-Income Countries. *JAMA Oncol*. epub: -.
Published
59. Delos Santos S, Witzke N, Gyawali B, Arciero VS, Rahmadian AP, Everest L, Cheung MC, Chan KK. (2021). Reassessing the Net Benefit of Cancer Drugs With Evolution of Evidence Using the ASCO Value Framework. *Journal of NCCN*. epub: -.
Published
60. Merchant SJ, Kong W, Gyawali B, Hanna TP, Chung W, Nanji S, Patel SV, and Booth CM. (2021). First-Line Palliative Chemotherapy for Esophageal and Gastric Cancer: Practice Patterns and Outcomes in the General Population. *JCO Oncology Practice*. epub: -.
Published
61. West HJ and Gyawali B. (2021). Why Not Adore ADAURA? - The Trial We Need vs the Trial We Got. *JAMA Oncology*. 7(5): 677-78.
Published
62. Del Paggio JC, Berry JS, Hopman WM, Eisenhauer EA, Prasad V, Gyawali B and Booth C. (2021). Evolution of the Randomized Clinical Trial in the Era of Precision Oncology. *JAMA Oncol*. epub: -.
Published
63. Poudyal BS, Gyawali B, Rondelli D. (2020). The need for locally generated data in haematology: a real-world experience of aplastic anaemia in Nepal. *British Journal of Haematology*. ePub: -.
Published
Refereed?: Yes
64. Rubinstein SM, Sethi T, Venepalli NK, Gyawali B, Schwartz C, Rivera DR. (2020). Chemotherapy Knowledge Base Management in the Era of Precision Oncology. *Journal of Clinical Oncology*. ePub: -.
Published
Refereed?: Yes
65. Robinson AG, Gyawali B, Evans G. (2020). COVID-19 and cancer: do we really know what we think we know?. *Nat Rev Clin Oncol*. 10: 386–388.
Published
Refereed?: Yes
66. Desai A and Gyawali B. (2020). Financial toxicity of cancer treatment: Moving the discussion from acknowledgement of the problem to identifying solutions. *Eclinicalmedicine*, Published by the Lancet. 20: -.
Published
Refereed?: Yes

67. Gyawali B, West HJ. (2020). Lessons From ADAURA on Adjuvant Cancer Drug Trials: Evidence, Ethics, and Economics. *Journal of Clinical Oncology*. ePub: -.
Published
Refereed?: Yes
68. Gyawali B, Hey SP and Kesselheim AS. (2020). Evaluating the evidence behind the surrogate measures included in the FDA's table of surrogate endpoints as supporting approval of cancer drugs. *Eclinicalmedicine*, Published by the Lancet. 21: -.
Published
Refereed?: Yes
69. Sedhom R and Gyawali B. (2020). When is a suboptimal approach to cancer screening better than none?. *AMA Journal of Ethics*. 22(2): E93-101.
Published
Refereed?: Yes
70. Desai A, Kulkarni A, Rajkumar SV and Gyawali B. (2020). Clinical Trial End Points in Severe COVID-19. *Mayo Clinic Proceedings*. 95(8): 1578-1580.
Published
Refereed?: Yes
71. Gyawali B, Poudyal BS, Eisenhauer EA. (2020). Covid-19 Pandemic—An Opportunity to Reduce and Eliminate Low-Value Practices in Oncology?. *JAMA Oncol*. 6(11): 1693-4.
Published
Refereed?: Yes
72. Sharma PB, Gyawali B, Rondelli D. (2020). Rapidly established telehealth care for blood cancer patients in Nepal during the COVID-19 pandemic using the free app Viber. *ecancer*. 14: 104.
Published
Refereed?: Yes
73. Gupta A, Wang P, Ali SA, Rajkumar SV, Gyawali B, Overton HN, Makary MA. (2020). Use of Bone-Modifying Agents Among Medicare Beneficiaries With Multiple Myeloma. *JAMA Oncol*. 6(2): 296-8.
Published
Refereed?: Yes
74. Poudyal BS, Giri S, Tuladhar S, Neaupane S and Gyawali B. (2020). A survey in Nepalese patients with acute leukaemia: a starting point for defining financial toxicity of cancer care in low-income and middle-income countries. *The Lancet Haematology*. 7(9): e638-639.
Published
Refereed?: Yes
75. Merchant SJ, Kong W, Gyawali B, Hanna T, Chung W, Nanji S, Patel SV, Booth CM. (2020). Effectiveness of Trastuzumab in Routine Clinical Practice: A Population-based Study of Patients with HER-2-positive Oesophageal, Gastroesophageal and Gastric Cancer. *Clin Oncol (R Coll Radiol)*. -: -.
In Press
Refereed?: Yes
76. Trotta F, Mayer F, Barone-Adesi F, Esposito I, Punreddy R, Da Cas R, Traversa G, Perrone F, Martini N, Gyawali B, Addis A. (2020). Anticancer drug prices and clinical outcomes: a cross-sectional study in Italy. *BMJ Open*. 6(2): 296-298.
Published
Refereed?: Yes
77. Ginsburg O, Yip CH, Brooks A, Cabanes A, Caleffi M, Yataco JAD, Gyawali B et al. (2020). Breast cancer early detection: A phased approach to implementation. *Cancer*. 126: 2379-2393.
Published
Refereed?: Yes

78. Gyawali B, Sharma S#, Shilpakar R, Dulal S, Pariyar J, Booth CM, Sharma Poudyal B. (2020). Overview of Delivery of Cancer Care in Nepal: Current Status and Future Priorities. JCO Global Oncology. 6: 1211-1217.
Published
Refereed?: Yes
79. Raphael MB, Gyawali B and Booth CM. (2020). Challenges and opportunities for cancer clinical trials in low- and middle-income countries. Nature Cancer. 1: 142-5.
Published
Refereed?: Yes
80. Wijeratne DT, Hammad N and Gyawali B. (2020). Gender differences in outcomes of cancer patients with COVID: Signal or noise?. Eclinicalmedicine. 26: 100535.
Published
Refereed?: No
81. Gyawali B, D'Andrea E, Franklin JM and Kesselheim AS. (2020). Response Rates and Durations of Response for Biomarker-Based Cancer Drugs in Nonrandomized Versus Randomized Trials. Journal of NCCN. 18: -.
Published
Refereed?: Yes
82. Desai A, Gyawali B. (2020). Assessing the benefits and harms of direct oral anticoagulants in patients with cancer for the prophylaxis and treatment of venous thromboembolism: a systematic review and meta-analysis. ecancer. 14: 1091.
Published
Refereed?: Yes
83. Datta SS, Mukherjee A, Ghose S, Bhattacharya S, Gyawali B. (2020). Addressing the Mental Health Challenges of Cancer Care Workers in LMICs During the Time of the COVID-19 Pandemic. JCO Glob Oncol. 6: 1490-1493.
Published
Refereed?: Yes
84. Desai A and Gyawali B. (2020). Endpoints used in phase III randomized controlled trials of treatment options for COVID-19. Eclinicalmedicine, Published by the Lancet. 23: -.
Published
Refereed?: Yes
- [85.](#) Desai A and Gyawali B. (2020). Fall in US cancer death rates: Time to pop the champagne?. Eclinicalmedicine, Published by the Lancet. 19: 100279.
Published
Refereed?: Yes
86. Gyawali B and Niraula S. (2020). Lessons from Adaptive Randomization: Spying the I-SPY2 trial in breast cancer. Journal of NCCN. 18(11): 1441.
Published
Refereed?: Yes
87. Gyawali B* and West J. (2020). LessonsFrom ADAURA on Adjuvant Cancer Drug Trials: Evidence, Ethics, and Economics. Journal of Clinical Oncology. epub: -.
Published
88. Raphael MB, Gyawali B and Booth CM. (2020). Real world evidence and regulatory drug approval. Nature Reviews Clinical Oncology. 17: 271–272.
Published
Refereed?: Yes

89. Effing S and Gyawali B. (2020). Assessing the risk-benefit profile of ramucirumab in patients with advanced solid tumors: A meta-analysis of randomized controlled trials. *Eclinicalmedicine*, Published by the Lancet. -:
Published
Refereed?: Yes
- [90.](#) Addeo A, Weiss GW and Gyawali B. (2019). Association of Industry and Academic Sponsorship With Negative Phase 3 Oncology Trials and Reported Outcomes on Participant SurvivalA Pooled Analysis. *JAMA Netw Open*. 2(5): e193684.
Published
Refereed?: Yes
91. Naci H, Davis C, Savović J, Higgins JPT, Sterne JAC, Gyawali B, Romo-Sandoval X, Handley N, Booth CM. (2019). Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancerdrugs by European Medicines Agency, 2014-16: cross sectional analysis. *BMJ*. epub: -.
Published
Refereed?: Yes
- [92.](#) Mamtani, R. , Wang, X. V., Gyawali, B. , DiPaola, R. S., Epperson, C. N., Haas, N. B. and Dutcher, J. P. (2019). Association between age and sex and mortality after adjuvant therapy for renal cancer. *Cancer*. 125(10): 1637-1644.
Published
Refereed?: Yes
93. Gyawali B. (2019). Multiple approvals, celestial prices, unimproved outcomes: the tale of cost-ineffective drugs in hepatocellular carcinoma. *Journal of NCCN*. 17(6): -.
Published
Refereed?: Yes
- [94.](#) Gyawali B and Prasad V. (2019). Making adjuvant therapy decisions with uncertain data. *Annals of Oncology*. 30: 361-4.
Published
Refereed?: Yes
- [95.](#) Gyawali B, Hey SP, Kesselheim AS. (2019). Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval. *JAMA Internal Medicine*. 179: 906-913.
Published
Refereed?: Yes
- [96.](#) Parikh RB, Galsky MD, Gyawali B, Riaz F, Kauffman T, Cohen AB, Adamson BJS, Gross CP, Meropol NJ and Mamtani R. (2019). Trends in Checkpoint Inhibitor Therapy for Advanced Urothelial Cell Carcinoma at the End of Life: Insights from Real-World Practice. *The Oncologist*. 24(6): e397-e399.
Published
Refereed?: Yes
97. Gyawali B, Sharma S# and Booth CM. (2019). Is the number of cancer drug approvals a surrogate for regulatory success?. *Journal of Cancer Policy*. 22: -.
Published
Refereed?: Yes
- [98.](#) Honda K, Gyawali B, Ando M, Kumanishi R, Kato K, Sugiyama K, Mitani S, Masuishi T, Narita Y, Bando H, Taniguchi H, Kadowaki S, Ura T, and Muro K. (2019). Prospective Survey of Financial Toxicity Measured by the Comprehensive Score for Financial Toxicity in Japanese Patients With Cancer. *Journal of Global Oncology*. 5: 1-8.
Published
Refereed?: Yes

99. Gyawali B, Tessema FA, Jung EH, Kesselheim AS. (2019). Assessing the Justification, Funding, Success, and Survival Outcomes of Randomized Noninferiority Trials of Cancer Drugs: A Systematic Review and Pooled Analysis. *JAMA Netw Open*. 2(8): e199570.
Published
Refereed?: Yes
100. Gyawali B, Bouche G, Pantziarka P, Kesselheim AS, Sarpatwari A. (2019). Lung Cancer Survival Gains: Contributions of Academia and Industry. *J Law Med Ethics*. 47(3): 357–361.
Published
Refereed?: Yes
101. Passaro A, Spitaleri G, Gyawali B and de Marinis F. (2019). Immunotherapy in Non–Small-Cell Lung Cancer Patients With Performance Status 2: Clinical Decision Making With Scant. *Journal of Clinical Oncology*. 37(22): 1863-7.
Published
Refereed?: Yes
102. Gyawali B and Kesselheim AS. (2019). The promise of ESCAT: a new system for evaluating cancer drug–target pairs. *Nature Reviews Clinical Oncology*. 16: 147–148.
Published
Refereed?: Yes
103. Hey SP, D'Andrea E, Jung EH#, Tessema F#, Luo J, Gyawali B and Kesselheim AS. (2019). Challenges and opportunities for biomarker validation. *J Law Med Ethics*. 47(3): 357-361.
Published
Refereed?: Yes
104. Gyawali B and Kesselheim AS. (2019). US Food and Drug Administration Approval of New Drugs Based on Noninferiority Trials in Oncology A Dangerous Precedent?. *JAMA Oncology*. 5(5): 607-8.
Published
Refereed?: Yes
105. Hey SP, Gyawali B, D'Andrea E, Kanagaraj M, Franklin JM, Kesselheim AS. (2019). A Systematic Review and Meta-analysis of Bevacizumab in First-line Metastatic Breast Cancer: Lessons for the Research and Regulatory Enterprises. *J Natl Cancer Inst*. 112(4): 335–342.
Published
Refereed?: Yes
106. Hwang TJ, Kesselheim AS and Gyawali B. (2018). Affordability and Price Increases of New Cancer Drugs in Clinical Guidelines, 2007-2016. *JNCI Cancer Spectrum*. 2(2): -.
Published
Refereed?: Yes
107. Gyawali B, Shimokata T, Honda K and Ando Y. (2018). Reporting harms more transparently in trials of cancer drugs. *The BMJ*. 363: k4383.
Published
Refereed?: Yes
108. Gyawali B and West J. (2018). Plasma vs Tissue Next-Generation Sequencing in Non–Small Cell Lung Cancer—Either, Both, or Neither?. *JAMA Oncology*. 5(2): 148-149.
Published
Refereed?: Yes
109. Gyawali B and Kesselheim AS. (2018). Reinforcing the social compromise of accelerated approval. *Nature Reviews Clinical Oncology*. 15: 596–597.
Published
Refereed?: Yes

110. Honda K, Gyawali B, Ando M, et al. (2018). A prospective survey of comprehensive Score for financial Toxicity in Japanese cancer patients: report on a pilot study. *ecancermedicalsecience*. 12: 847.
Published
Refereed?: Yes
- [111.](#) Weir I.R , Marshall G.D., Schneider JI, Sherer JA, Lord EM, Gyawali B, Pasasche-Orlow MK, Benjamin EJ and Trinquart L. (2018). Interpretation of Time-to-event Outcomes in Randomized Trials: an online randomized experiment. *Annals of Oncology*. 30(1): 96-102.
Published
Refereed?: Yes
- [112.](#) 44. Gyawali B. (2018). Does global oncology need artificial intelligence?. *The Lancet Oncology*. 19(5): P599-600.
Published
Refereed?: Yes
113. Breast Cancer Res Treat. (2018). Optimal duration of adjuvant trastuzumab in treatment of early breast cancer: a meta-analysis of randomized controlled trials. *Breast Cancer Res Treat*. 173: 103–109.
Published
Refereed?: Yes
- [114.](#) Gyawali B and Addeo A. (2018). Negative Phase 3 Randomized Controlled Trials: Why cancer drugs fail the last barrier?. *International Journal of Cancer*. 143(8): 2079-2081.
Published
Refereed?: Yes
- [115.](#) Gyawali B, Patziarka P, Crispino S and Bouche G. (2018). Does the oncology community have a rejection bias when it comes to repurposed drugs?. *Ecancer*. 76: -.
Published
- [116.](#) Hwang TJ and Gyawali B. (2018). Association between progression-free survival and patients' quality of life in cancer clinical trials. *International Journal of Cancer*. 144(7): 1746-1751.
Published
Refereed?: Yes
- [117.](#) Ido S, Gyawali B and Goldstein D. (2018). Duration of adjuvant immunotherapy—biologic, clinical and economic considerations. *Medical Oncology*. 160: -.
Published
Refereed?: Yes
118. Gyawali B and Lopes G. (2018). What Global Oncology Needs: Mutual Learning and More Funding. *Journal of Global Oncology*. 4: 1-3.
Published
Refereed?: Yes
- [119.](#) Pantziarka P, Verbaanderd C, Sukhatme V, Capistrano R, Crispino S, Gyawali B, Rooman I, Van Nuffel A, Meheus L, Sukhatme VP and Bouche G. (2018). ReDO_DB: the repurposing drugs in oncology database. *Ecancermedicalsecience*. 12: 886.
Published
Refereed?: Yes
- [120.](#) Gyawali B. (2018). Meta-analyses and RCTs in oncology: what is the right balance?. *The Lancet Oncology*. 19(12): P1565-1566.
Published
Refereed?: Yes
121. Gyawali B, Kesselheim AS and d'Andrea Elvira. (2018). Does Helicobacter pylori eradication therapy to prevent gastric cancer increase all-cause mortality?. *International Journal of Cancer*. 144(2): 411-412.
Published
Refereed?: Yes

122. Gyawali B and Niraula S. (2018). Cancer treatment in the last 6 months of life: when inaction can outperform action. *Ecancermedicalsecience*. 12: 826.
Published
Refereed?: Yes
123. Hwang TJ, Franklin JM, Chen CT, Lauffenburger JC, Gyawali B, Kesselheim AS and Darrow JJ. (2018). Efficacy, Safety, and Regulatory Approval of Food and Drug Administration–Designated Breakthrough and Nonbreakthrough Cancer Medicines. *Journal of Clinical Oncology*. 36(18): 1805-1812.
Published
Refereed?: Yes
124. Bhatt VR, Chen B, Gyawali B and Lee SJ. (2018). Socioeconomic and health system factors associated with lower utilization of hematopoietic cell transplantation in older patients with acute myeloid leukemia. *Bone Marrow Transplant*. 53: 1288–1294.
Published
Refereed?: Yes
- [125.](#) Gyawali B, Hey SP and Kesselheim AS. (2018). Correlation and differences in effect sizes between progression-free survival and overall survival with PD-1 inhibitors. *JAMA Network Open*. 1(2): e180416.
Published
Refereed?: Yes
126. Gyawali B and Goldstein D. (2018). The US Food and Drug Administration's Approval of Adjuvant Sunitinib for Renal Cell Cancer: A Case of Regulatory Capture?. *JAMA Oncology*. 4(5): 623-624.
Published
Refereed?: Yes
- [127.](#) Gyawali B and Prasad V. (2017). Drugs that lack single-agent activity: are they worth pursuing in combination?. *Nature Reviews Clinical Oncology*. 14(4): 193-4.
Published
Refereed?: Yes
- [128.](#) Gyawali B and Ando Y. (2017). Adjuvant Sunitinib for high-risk resected renal cell carcinoma: a meta-analysis of ASSURE and S-TRAC trials. *Annals of Oncology*. 28(4): P898-899.
Published
Refereed?: Yes
129. Gyawali B, Shimokata T, Ando M, Honda K and Ando Y. (2017). Risk of Serious Adverse Events and Fatal Adverse Events with Sorafenib use in Patients with Solid Cancer: A meta-analysis of phase 3 Randomized Controlled Trials. *Annals of Oncology*. 28(2): 246-253.
Published
Refereed?: Yes
130. Gyawali B. (2017). Biosimilars in Oncology: everybody agrees but nobody uses?. *Recenti Progressi in Medicina*. 108: 173-175.
- [131.](#) Adhikari J, Gyawali B, Sharma P and Bhatta VR. (2017). Outcomes of haploidentical transplant compared with matched donor allogeneic stem cell transplant. *Future Oncology*. 13(10): 935-944.
Published
Refereed?: Yes
- [132.](#) Gyawali B. (2017). The OlympiAD trial: Who Won the Gold?. *ecancer*. 11: -.
Published
Refereed?: Yes
- [133.](#) Gyawali B and Prasad V. (2017). Pemetrexed in Nonsquamous Non–Small-Cell Lung Cancer: The Billion Dollar Subgroup Analysis. *JAMA Oncology*. 4(1): 17–18.
Published
Refereed?: Yes

134. Gyawali B. (2017). Cancer Drugs in LMICs: cheap but unaffordable. *Oncotarget*. 8: 89425-89426.
Published
Refereed?: Yes
135. Tsukuura H, Miyazaki M, Morita T, Sugishita M, Kato H, Murasaki Y, Gyawali B, Kubo Y, Ando M, Kondo M, Yamada K, Hasegawa Y and Ando Y. (2017). Efficacy of Prophylactic Treatment for Oxycodone-Induced Nausea and Vomiting Among Patients with Cancer Pain (POINT): A Randomized, Placebo-Controlled, Double-Blind Trial. *The Oncologist*. 23(3): 367-374.
Published
Refereed?: Yes
- [136.](#) Gyawali B. (2017). Low-value practices in oncology contributing to financial toxicity. *ecancer*. 11: 727.
Published
Refereed?: Yes
- [137.](#) Gyawali B and Prasad V. (2017). Health policy: Me-too drugs with limited benefits - the tale of regorafenib for HCC. *Nature Reviews Clinical Oncology*. 11: 653-654.
Published
Refereed?: Yes
138. Gyawali B. (2017). Biosimilars in Oncology: everybody agrees but nobody uses?. *Recenti Progressi in Medicina*. 108: 173-5.
Published
Refereed?: Yes
- [139.](#) Gyawali B and Prasad V. (2017). Combining drugs and extending treatment-a PFS endpoint is not sufficient. *Nature Reviews Clinical Oncology*. 14(9): 521-522.
Published
Refereed?: Yes
- [140.](#) Gyawali B, Parsad S, Feinberg B and Nabhan C. (2017). **Real-World Evidence and Randomized Studies in the Precision Oncology Era: The Right Balance**. *JCO Precision Oncology*. 1: -.
Published
Refereed?: Yes
141. Gyawali B. (2017). Cancer Drugs in LMICs: cheap but unaffordable. *Oncotarget*. 8(52): 89425.
- [142.](#) Gyawali B and Iddawela M. (2017). Bevacizumab in advanced cervical cancer: issues and challenges for low- and middle- income countries. *Journal of Global Oncology*. 3(2): 93-7.
Published
Refereed?: Yes
143. Fernandes R, Mazzarello S, Stober C, Ibrahim MFK, Dudani S, Perdrizet K, Majeed H, Vandermeer L, Shorr R, Hutton B, Fergusson D, Gyawali B, and Clemons M. (2017). Primary Febrile Neutropenia Prophylaxis for Patients Who Receive FEC-D Chemotherapy for Breast Cancer: A Systematic Review. *Journal of Global Oncology*. 4: 1-8.
Published
Refereed?: Yes
144. Gyawali B and Niraula S. (2017). Duration of adjuvant trastuzumab in HER2 positive breast cancer: Overall and disease free survival results from meta-analyses of randomized controlled trials. *Cancer Treatment Reviews*. 60: P18-23.
Published
Refereed?: Yes
- [145.](#) Gyawali B and Sullivan R. (2017). Economics of Cancer Medicines: for whose benefit?. *The New Bioethics*. 23(1): 95-104.
Published
Refereed?: Yes

- [146.](#) Gyawali B. (2017). The Imprecise Pursuit of Precision Medicine: Are biomarkers to blame?. Journal of the NCCN. 15(7): 859-862.
Published
Refereed?: Yes

Book Chapters

1. Sharland M, Zanichelli V, Gyawali B, Sengar M, Cappello B, Moja L and Huttner B. (2022). Being AWaRe of the risk of inappropriate antibiotic use in people living with cancer.WHO. AMR Control Supplement: The Challenge For The Cancer Community.
Published, WHO, Switzerland
2. Mutebi M, Dehar N, Nogueira LM, Shi K, Yabroff KR, Gyawali B. (2022). Cancer Groundshot: Building a Robust Cancer Control Platform in Addition To Launching the Cancer Moonshot.ASCO. American Society of Clinical Oncology Book.
Published, ASCO, United States of America
3. Leighl NB, Nirmalakumar S, Ezeife DA, Gyawali B. (2021). An Arm and a Leg: The Rising Cost of Cancer Drugs and Impact on Access.ASCO. American Society of Clinical Oncology Book.
Published, ASCO, United States of America
4. Andres JMB, Gyawali B, Krakauer E and Trapani D. (2020). Cancer management. N/A. WHO Report on Cancer: setting priorities, investing wisely and providing care for all.
Published, World Health Organization, Switzerland
5. Gyawali B. (2019). Causes, Consequences, and Control of High Cancer Drug Prices. Dr. Eric H. Bernicker. Cancer and Society.
Published, Springer, Switzerland
6. Gyawali B, Hwang TJ, Vokinger KN, Booth CM, Amir E and Tibau A. (2019). Patient-Centered Cancer Drug Development: Clinical Trials, Regulatory Approval, and Value Assessment. N/A. American Society of Clinical Oncology Educational Book 39.
Published, American Society of Clinical Oncology, United States of America

Conference Publications

1. Ramy Saleh, Philippe L. Bedard, Paul Nguyen, Eoghan Ruadh Malone, Celeste Yu, Eitan Amir, Craig Earle, Bishal Gyawali, Aaron Richard Hansen, Nicole Mittmann, Yingwei Peng, Trevor John Pugh, Albiruni Ryan Abdul Razak, Peter Sabatini, Anna Spreafico, Tracy Stockley, Jonathon Torchia, Christine Williams, Lillian L. Siu, Timothy Hanna. An evaluation of administrative data linkage for measurement of real-world outcomes of large clinical panel sequencing for advanced solid tumors.ASCO Quality Care Symposium, Conference Date: 2020/10
Abstract
2. Ramy Saleh, Philippe L. Bedard, Paul Nguyen, Eoghan Ruadh Malone, Celeste Yu, Eitan Amir, Craig Earle, Bishal Gyawali, Aaron Richard Hansen, Nicole Mittmann, Yingwei Peng, Trevor J Pugh, Albiruni Ryan Abdul Razak, Peter Sabatini, Anna Spreafico, Tracy Stockley, Jonathon Torchia, Christine Williams, Lillian L. Siu, Timothy P Hanna. An evaluation of administrative data linkage for measurement of real-world outcomes of large clinical panel sequencing for advanced solid tumors.ASCO Virtual Scientific Program, Conference Date: 2020/5
Abstract

3. Connor Wells, Shubham Sharma, Joey C. Del Paggio, Wilma M. Hopman, Bishal Gyawali, CS Pramesh, Richard Sullivan, Christopher M. Booth. Global perspectives on clinical cancer research: A comparison of randomized controlled trial (RCT) design and outcomes across high income and low-middle income countries.ASCO Virtual Scientific Program,
Conference Date: 2020/5
Abstract
4. Ali Raza Khaki, Aakash Desai, Martin W. Schoen, Bishal Gyawali, Eddy J. Chen, Peter C. Yang, Jeremy Lyle Warner. Timing of US Food and Drug Administration (FDA) cancer drug approvals relative to publication of clinical trial results.ASCO Virtual Scientific Program,
Conference Date: 2020/5
Abstract
5. Shubham Sharma, Connor Wells, Joey C. Del Paggio, Wilma M. Hopman, Bishal Gyawali, C S. Pramesh, Richard Sullivan, Christopher M. Booth. Methodology, results, and publication of oncology clinical trials: Insights from all the world's randomized controlled trials (RCTs) 2014-2017.ASCO Virtual Scientific Program,
Conference Date: 2020/5
Abstract
6. Bishal Gyawali, Peter C. Yang, Sam Rubinstein, Martin W. Schoen, Ali Raza Khaki, Jeremy Lyle Warner. Mismatch between mortality burden and number of FDA registration trials in highly lethal cancers. ASCO Virtual Scientific Program,
Conference Date: 2020/5
Abstract
7. Gyawali B. Cancer Groundshot- The need for prioritization in Global Oncology. Annual ASTRO meeting,
Conference Date: 2020/3
Abstract, Invited?: Yes
8. Gyawali B. Implementation issues skewing the MCBS Scores. ESMO Annual Meeting,
Conference Date: 2020/3
Abstract, Invited?: Yes
9. Gyawali B. Regulatory barriers for cancer drug approvals: are they really necessary?. ESMO ASIA Congress 2019,
Conference Date: 2019/11
Abstract, Invited?: Yes
10. Gyawali B. Repurposing of Drugs in Oncology. Annual Scientific Congress of Malaysian Oncological Society (ASCOMOS 2019),
Conference Date: 2019/11
Abstract, Invited?: Yes
11. Gyawali B. Cancer Groundshot. eCancer Conference,
Conference Date: 2019/10
Abstract
12. Gyawali B. Clinical Trial Participation From the Patient Perspective. ASCO Annual Meeting,
Conference Date: 2019/5
Abstract
13. Gyawali B. Cost-effective chemotherapy use in low-resource setting. AORTIC meeting,
Conference Date: 2019/3
Abstract, Invited?: Yes
14. Gyawali B. Choosing Wisely in LMICs: Colorectal cancer and Lung cancer. AORTIC meeting,
Conference Date: 2019/3
Abstract, Invited?: Yes

15. Gyawali B. Balancing access to therapy with overtreatment in Low And Middle Income Countries. ASCO-AORTIC joint conference,
Conference Date: 2019/3
Abstract
16. Ravi Bharat Parikh, Matt D. Galsky, Bishal Gyawali, Fauzia Riaz, Tara Laura Kaufmann, Aaron Benjamin Cohen, Blythe J.S. Adamson, Cary Philip Gross, Neal J. Meropol, Ronac Mamtani. Trends in checkpoint inhibitor therapy for advanced urothelial cell carcinoma (aUC) at the end of life: Insights from real-world practice. Genitourinary Cancers Symposium,
Conference Date: 2019/2
Abstract
17. Gyawali B. Research Capacity building in low-and-middle-income countries.ESMO Asia Congress,
Conference Date: 2018/11
Abstract, Invited?: Yes
18. Gyawali B. Financial toxicity and out of pocket costs.World Conference on Lung Cancer,
Conference Date: 2018/9
Abstract, Invited?: Yes
19. Kazunori Honda, Bishal Gyawali, Masashi Ando, Kyoko Kato, Yuki Kojima, Seiichiro Mitani, Toshiki Masuishi, Yukiya Narita, Hiroya Taniguchi, Shigenori Kadowaki, Takashi Ura, Kei Muro. A prospective survey of comprehensive score for financial toxicity (COST) in Japanese cancer patients. ASCO Annual Meeting,
Conference Date: 2018/6
Abstract
20. Bishal Gyawali, Thomas Hwang. Prevalence of quality of life(QoL) outcomes and association with survival in cancer clinical trials.ASCO Annual Meeting,
Conference Date: 2018/6
Abstract
21. Gyawali B. New Technologies in cancer care: hope or hype?. 6th Annual Symposium on Global Cancer Research,
Conference Date: 2018/3
Abstract, Invited?: Yes
22. Bishal Gyawali, Kazunori Honda, Tomoya Shimokata, Yuichi Ando. The incidence and risks of adverse events in randomized controlled trials (RCTs) of cancer drugs downplaying the harms. ASCO Annual Meeting,
Conference Date: 2017/6
Abstract

Presentations

1. (2023). The final translational cancer research: improving patient outcomes in the real world. Inaugural Ontario Institute for Cancer Research Clinical Translational Annual Meeting, Canada
Main Audience: Researcher
Invited?: Yes, Keynote?: Yes
2. (2022). Cancer Groundshot. Clinical Trials in LMICs. ASCO 2022 Annual Meeting (Invited Speaker and Chair), United States of America
Main Audience: Knowledge User
Invited?: Yes, Keynote?: No

3. (2021). Chair and Invited Faculty, Education Session on Health Services Research and Health Economics. World Conference on Lung Cancer (online), Canada
Main Audience: Knowledge User
Invited?: Yes, Keynote?: No
4. (2021). Cancer Groundshot. European Cancer Summit, Belgium
Main Audience: Knowledge User
Invited?: Yes, Keynote?: Yes
5. (2019). Advances in Anticancer Therapy Delivery and Cancer Health Disparities Panel moderator. Summit on National and Global Cancer Health Disparities, United States of America
Main Audience: Knowledge User
Invited?: Yes, Keynote?: No

Knowledge and Technology Translation

2022/9	Health Policy Advisor, Policy/Regulation Development
2022/3	Member, Policy/Regulation Development Activity Description: Member of the team that developed a checklist for assessment of quality of life benefit from cancer drugs
2020/3	Primary Investigator, Technology, Product, Process, Service Improvement/Development Activity Description: I was the PI of the project to upgrade the ESMO-MCBS tool to include assessment of quality of evidence for evaluation of the magnitude of clinical benefit of cancer drugs.
2020/1	Working Group Member, Policy/Regulation Development Activity Description: WHO Essential Medicine List Cancer Drugs Working Group - translation of my expertise in deciding the drugs to include for the Essential Medicine List of WHO.
2020/1	Working Group Member, Policy/Regulation Development Activity Description: ESMO-MCBS Extended Working Group - Translation of my work on cancer drug trial issues to development of ESMO-MCBS scores and grading of QOL

Student/Postdoctoral Supervision

Bachelor's [n=1]

2019/9	Sophie Effing, Queen's University
Principal Supervisor	Thesis/Project Title: - Present Position: Undergraduate student in Biological Sciences

Master's Equivalent [n=3]

2020/9	Aarushi Sachdev, Queen's University
Principal Supervisor	Thesis/Project Title: - Present Position: Medical Student
2020/9	Joseph Samuel, Queen's University
Principal Supervisor	Thesis/Project Title: - Present Position: medical student, Queen's University

2020/1 Subham Sharma, Medical Student
Principal Supervisor Thesis/Project Title: -
Present Position: Medical Student, Queen's University

Doctorate [n=1]

2020/5 Melinda chelva, Queen's University
Co-Supervisor Thesis/Project Title: Using mHealth for cervical cancer screening in Tanzania
Present Position: Ongoing

Doctorate Equivalent [n=1]

2020/9 Aakash Desai, University of Connecticut
Principal Supervisor Thesis/Project Title: -
Present Position: Internal Medicine final year resident

Post-doctorate [n=4]

2022/1 Laure-Anne Teuwen, University Hospital Antwerp, Belgium
Academic Advisor Thesis/Project Title: -
Present Position: Medical Oncologist

2022/1 Adi Kartolo, Queen's University
Academic Advisor Thesis/Project Title: -
Present Position: Medical Oncology Fellow

2022/1 Navdeep Dehar, Queen's University
Academic Advisor Thesis/Project Title: **Medical Oncology Resident**
Present Position: Medical Oncology Resident

2021/1 Daniel Meyers, University of Alberta
Academic Advisor Thesis/Project Title: -
Present Position: Medical Oncology Resident